Clinical Trial

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Study acronym: BetaBart
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-19; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting 2026-01-13
Trial Details
NCT Number NCT07189871
Lead Sponsor Radiopharm Theranostics, Ltd
Collaborators: Medpace, Inc.
Conditions Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ) +2 more
Enrollment 61 participants
Start Date 2026-02-23
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-27